Vincent Chouraki1, Alexa Beiser2, Linda Younkin3, Sarah Rosner Preis4, Galit Weinstein5, Oskar Hansson6, Ingmar Skoog7, Jean-Charles Lambert8, Rhoda Au5, Lenore Launer9, Philip A Wolf5, Steven Younkin3, Sudha Seshadri5. 1. The Framingham Heart Study, Framingham, MA, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA. Electronic address: vchourak@bu.edu. 2. The Framingham Heart Study, Framingham, MA, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 3. Mayo Clinic, Jacksonville, FL, USA. 4. The Framingham Heart Study, Framingham, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 5. The Framingham Heart Study, Framingham, MA, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA. 6. Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden. 7. Neuropsychiatric Epidemiology Research Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. 8. Inserm UMR 744, Lille, France; Université Lille Nord de France, Lille, France; Institut Pasteur de Lille, Lille, France. 9. Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, MD, USA.
Abstract
BACKGROUND: Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. METHODS: A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. RESULTS: Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76‒0.98], P = .027) and AD (Aβ1-42: HR = 0.79 [0.69‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72‒0.96], P = .012). CONCLUSION: Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
BACKGROUND: Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. METHODS: A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. RESULTS: Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76‒0.98], P = .027) and AD (Aβ1-42: HR = 0.79 [0.69‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72‒0.96], P = .012). CONCLUSION: Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
Authors: K Blennow; G De Meyer; O Hansson; L Minthon; A Wallin; H Zetterberg; P Lewczuk; H Vanderstichele; E Vanmechelen; J Kornhuber; J Wiltfang; I Heuser; W Maier; C Luckhaus; E Rüther; M Hüll; H Jahn; H J Gertz; L Frölich; H Hampel; R Pernetzki Journal: J Nutr Health Aging Date: 2009-03 Impact factor: 4.075
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Michael J Pencina; Ralph B D'Agostino; Karol M Pencina; A Cecile J W Janssens; Philip Greenland Journal: Am J Epidemiol Date: 2012-08-08 Impact factor: 4.897
Authors: Rhoda Au; Sudha Seshadri; Philip A Wolf; Merrill Elias; Penelope Elias; Lisa Sullivan; Alexa Beiser; Ralph B D'Agostino Journal: Exp Aging Res Date: 2004 Oct-Dec Impact factor: 1.645
Authors: O L Lopez; L H Kuller; P D Mehta; J T Becker; H M Gach; R A Sweet; Y F Chang; R Tracy; S T DeKosky Journal: Neurology Date: 2008-04-09 Impact factor: 9.910
Authors: Pedro Pesini; Virginia Pérez-Grijalba; Inmaculada Monleón; Mercè Boada; Lluís Tárraga; Pablo Martínez-Lage; Itziar San-José; Manuel Sarasa Journal: Int J Alzheimers Dis Date: 2012-08-16
Authors: Yakeel T Quiroz; Aaron P Schultz; Kewei Chen; Hillary D Protas; Michael Brickhouse; Adam S Fleisher; Jessica B Langbaum; Pradeep Thiyyagura; Anne M Fagan; Aarti R Shah; Martha Muniz; Joseph F Arboleda-Velasquez; Claudia Munoz; Gloria Garcia; Natalia Acosta-Baena; Margarita Giraldo; Victoria Tirado; Dora L Ramírez; Pierre N Tariot; Bradford C Dickerson; Reisa A Sperling; Francisco Lopera; Eric M Reiman Journal: JAMA Neurol Date: 2015-08 Impact factor: 18.302
Authors: Vincent Chouraki; Sarah R Preis; Qiong Yang; Alexa Beiser; Shuo Li; Martin G Larson; Galit Weinstein; Thomas J Wang; Robert E Gerszten; Ramachandran S Vasan; Sudha Seshadri Journal: Alzheimers Dement Date: 2017-06-08 Impact factor: 21.566
Authors: Nicholas F Fitz; Victor Tapias; Andrea A Cronican; Emilie L Castranio; Muzamil Saleem; Alexis Y Carter; Martina Lefterova; Iliya Lefterov; Radosveta Koldamova Journal: Brain Date: 2015-10-28 Impact factor: 13.501
Authors: Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel Journal: Alzheimers Dement Date: 2016-11-18 Impact factor: 21.566
Authors: Juan Carlos Polanco; Chuanzhou Li; Liviu-Gabriel Bodea; Ramon Martinez-Marmol; Frederic A Meunier; Jürgen Götz Journal: Nat Rev Neurol Date: 2017-12-15 Impact factor: 42.937
Authors: Charlotte Andersson; Andrew D Johnson; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan Journal: Nat Rev Cardiol Date: 2019-11 Impact factor: 32.419
Authors: Shorena Janelidze; Niklas Mattsson; Sebastian Palmqvist; Ruben Smith; Thomas G Beach; Geidy E Serrano; Xiyun Chai; Nicholas K Proctor; Udo Eichenlaub; Henrik Zetterberg; Kaj Blennow; Eric M Reiman; Erik Stomrud; Jeffrey L Dage; Oskar Hansson Journal: Nat Med Date: 2020-03-02 Impact factor: 53.440
Authors: Kevin J Sullivan; Chad Blackshear; Jeannette Simino; Adrienne Tin; Keenan A Walker; A Richey Sharrett; Steven Younkin; Rebecca F Gottesman; Michelle M Mielke; David Knopman; B Gwen Windham; Michael E Griswold; Thomas H Mosley Journal: Neurology Date: 2021-08-04 Impact factor: 11.800